Please assess the completion status of the following clinical trial:

Trial Title: Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥18 and ≤85 years of age~2. Recent onset of symptomatic newly diagnosed or paroxysmal AF~   1. Recent onset is defined as a symptom duration ≥1 and ≤48 hours at time of dosing~  2. Newly diagnosed AF is AF that has not been diagnosed previously, independent of its duration~  3. Paroxysmal AF is defined as recurrent AF in a patient whose previous AF episode(s) self-terminated (ie, without treatment) or terminated with intervention ≤7 days of onset.~  4. A symptomatic recent-onset AF episode post cardiac ablation for paroxysmal AF would be considered eligible~Exclusion Criteria:~1. History of non self-terminating AF/AFL as defined by~   1. One or more failed attempts to restore SR with pharmacological therapy~  2. ECV procedure for an AF episode ≤1 year prior to screening. Exception: One (1) prior ECV is allowed if no option for pharmacological conversion was previously available~  3. More than 3 ECV procedures in ≤5 years prior to screening~2. Current diagnosis of persistent AF~   1. Persistent AF defined as AF that is continuously sustained \>7 days, including episodes terminated by cardioversion (drugs or electrical cardioversion) after \>7 days. Patients with persistent AF do not have self-terminating AF episodes~  2. Patients who have undergone an ablation procedure for persistent AF are not eligible~3. One or more episodes of AFL ≤6 months prior to randomization~   a. Exception: a patient who has received ablation for AFL ≤3 months prior to screening with no recurrence of AFL prior to randomization is considered eligible Vital signs~4. Hemodynamic or cardiac instability during AF, defined as any of the following:~   1. Systolic blood pressure \<100 or ≥160 mmHg~  2. Diastolic blood pressure ≥95 mmHg~  3. Ventricular heart rate \<80 or \>160 bpm~5. Respiratory rate \>22 breaths per minute Relevant structural heart disease~6. History of decompensated heart failure (HF)~7. Evidence of significant HF defined as any of the following:~   a. Hospitalization in the last 12 months for HF or suspected HF event b. Most recent assessment of left ventricular ejection fraction (LVEF) \<45% i. For patients in the United States, a standard diagnostic echocardiogram assessed ≤180 days prior to screening is required to ascertain eligibility. If none is available, the patient must undergo a standard diagnostic echocardiogram or a diagnostic echocardiogram using a portable ultrasound device (handheld echocardiogram \[HHE\]) during screening to confirm eligibility c. New York Heart Association (NYHA) Class II-IV symptoms d. Medication history suggestive of HF per the Investigator's discretion~8. Signs or symptoms of ongoing myocardial ischemia, including any of the following:~   1. Significant ST segment elevation or depression (ie, ≥2 mm) on a standard 12-lead ECG~  2. Echocardiogram findings (eg, wall motion abnormalities) suggestive of acute myocardial infarction (MI)~  3. Angina pectoris, atypical angina pectoris, or receiving antianginal medication for ischemia~9. History of MI ≤3 months of screening~10. History of uncorrected moderate or severe aortic or mitral valvular stenosis, in the opinion of the Investigator~    a. If an echocardiogram is performed at screening, moderate or severe valve disease observed during the examination is considered exclusionary~11. History of LV hypertrophy with LV thickness \>12 mm as observed in the most recent assessment, ie, an echocardiogram Other CV conditions~12. Stroke (including transient ischemic attack) ≤3 months prior to randomization~13. History of any of the following cardiac abnormalities:~    1. Long QT syndrome~   2. Conduction system disease (eg, PR interval \>200 ms, second- or third degree heart block, bundle branch block)~   3. Brugada syndrome~   4. Torsade de pointes~   5. Diagnosed with sinus node dysfunction (eg, sick sinus syndrome) or any of the following:~    i. History of unexplained or cardiovascular syncope ii. Bradycardia suggestive of sinus node dysfunction iii. Prior electrical or pharmacological cardioversion associated with sinus or ventricular pause \>3 seconds or ventricular heart rate \<45 bpm at time of conversion~14. Any of the following ECG-related features at screening:~    1. QT interval corrected for heart rate using the Fridericia formula (QTcF) \>480 msec~   2. Wide QRS complex (ie, duration ≥120 msec) or history of documented wide QRS complex tachycardia (ie, wide QRS complex with ventricular heart rate \>100 bpm)~   3. Presence of ventricular tachycardia (VT). Site telemetry should be equipped with an alarm system for VT and PVCs or be continuously visually observed prior to dosing~15. Presence of a pacemaker~16. Cardiac surgery for any of the exclusionary conditions (eg, valvular disease, hypertrophy, coronary artery disease) ≤6 months prior to randomization Prior and concomitant non-CV conditions~17. Known severe renal impairment or patient receiving dialysis~18. Known abnormal liver function, including hepatic disease or biochemical evidence of significant liver derangement~19. Uncorrected hypokalemia~    1. Hypokalemia is defined as serum potassium below the normal range according to the local laboratory reference ranges at screening~   2. If serum potassium is below the normal range at screening, therapeutic correction (eg, potassium supplementation) is required~20. Uncorrected hypomagnesemia~    1. Hypomagnesemia is defined as serum magnesium below the normal range according to the local laboratory reference ranges at screening~   2. If serum magnesium result is below the normal range at screening, therapeutic correction (eg, magnesium supplementation) is required~21. Chronic obstructive pulmonary disease or other established pulmonary disease in need of inhalation medication~    a. Exception: patients with intermittent mild asthma who are not experiencing active symptoms at screening, and whose asthma is well controlled with as-needed administration of a bronchodilator ≤2 days/week, and who has not experienced ≥2 exacerbations requiring oral systemic corticosteroids ≤1 year prior to screening~22. History of bronchospasm (eg, hyperreactive airways to inhalants) or difficulty inhaling medications~23. Previous or current hospitalization for COVID-19, or any secondary cardiomyopathy from COVID-19 Prior and concomitant medications and procedures~24. Treatment with Class I or III AADs ≤7 days prior to randomization~25. Treatment with amiodarone ≤12 weeks prior to randomization~26. Known hypersensitivity to flecainide acetate, any active metabolites of flecainide acetate, or any excipients in FlecIH-103~27. Any condition or circumstance which in the opinion of the Investigator may make the patient unsuitable for the study, such as:~    1. High risk for stroke based on the screening coagulation panel or medical history per Investigator's discretion (eg, CHA2DS2-VASc score)~   2. Congenital heart disease~   3. AF that is secondary to electrolyte imbalance, thyroid disease, or other reversible or non-cardiovascular cause~   4. A serious or life-threatening medical condition~   5. An acute infection~28. Known drug or alcohol dependence ≤12 months prior to screening as judged by the Investigator~29. A body mass index ≥35 kg/m2~30. Legally incompetent to provide informed consent~31. Previous treatment with any other investigational drug ≤30 days from screening or 5 half-lives of the drug, whichever is longer~32. Female of childbearing potential defined as any of the following:~    1. Not surgically sterile or postmenopausal (Appendix 1)~   2. A negative pregnancy test is unavailable at screening~   3. Pregnant or breastfeeding at screening~33. Males whose sexual partners are women of childbearing potential (WOCBP) must use at least one highly effective method of contraception during the study unless permenantly sterile by bilateral orchiectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- FlecIH-103 (flecainide acetate inhalation solution) (Type: ACTIVE_COMPARATOR): Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1. Dosing will continue until conversion of AF to SR is observed for ≥1 minute or the full dose (120 mg eTLD) is administered, whichever occurs first.
- Vehicle-matched inhalation solution (placebo) (Type: PLACEBO_COMPARATOR): Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).